Story thread · 2 reports / 1 sources

#EASD26: Lilly's triple-G allows 60% of patients to drop below obesity threshold

endpts.com · 19h · first reportShare

MILAN — Lilly said Tuesday that its triple agonist, called retatrutide, helped patients with both obesity and type 2 diabetes to lose up to 18.8% of their weight after about a year and a half. Also ...